<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02923128</url>
  </required_header>
  <id_info>
    <org_study_id>2015-01-13</org_study_id>
    <nct_id>NCT02923128</nct_id>
  </id_info>
  <brief_title>Whether Dexmedetomidine Can Improve the Prognosis of Elderly Patients With Postoperative Cognitive Dysfunction</brief_title>
  <official_title>Whether Dexmedetomidine Can Improve the Prognosis of Elderly Patients With Postoperative Cognitive Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether postoperative analgesia pump continuous&#xD;
      infusion of dexmedetomidine are effective in the prevention of Postoperative delirium and&#xD;
      Postoperative cognitive dysfunction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. collection of cases: This trail is approved by Hospital Ethics Committee, and patients&#xD;
           who participated in the study signed the informed consent. The subject will select 150&#xD;
           elder patients (age ≥65 years) routine tumor surgery, American Society of&#xD;
           Anesthesiologists classification-Ⅲ. Preoperative liver and kidney function, blood&#xD;
           electrolytes were in the normal range.&#xD;
&#xD;
        2. Case group: Selected cases divided into the right dexmedetomidine group and control&#xD;
           group by computer randomly, 75 patients in each group. Dexmedetomidine group (A group)&#xD;
           analgesia pump formula is: fentanyl 100ug + dexmedetomidine 150 ug, with 0.9% saline&#xD;
           diluted to 150ml. Control group (group C) postoperative analgesia formula is: fentanyl&#xD;
           150ug, with 0.9% saline diluted to 150ml. Two group with the same anesthesia program.&#xD;
           Venous blood serum is taken before surgery, at the before end of surgery and when&#xD;
           postoperative analgesia medication runs out (postoperative day 4) to test apolipoprotein&#xD;
           E, Amyloid-β1-42, Amyloid-β1-40, N-terminal pro B-type natriuretic peptide.&#xD;
&#xD;
        3. Post operative delirium and postoperative cognitive dysfunction diagnosis: Patients&#xD;
           completed neuropsychological tests at entry to the study-generally the day before&#xD;
           surgery-and at discharge from hospital or 1 week. The investigators assessed delirium by&#xD;
           the Confusion Assessment Method for the intense care unit. The neuropsychological tests&#xD;
           include Wechsler Adult Intelligence Scale-Revised by China Visual Reproduction、Wechsler&#xD;
           Adult Intelligence Scale-Revised by China Digit Span、Digit-Symbol Substitution Test、The&#xD;
           Stroop Color-Word Test、Trail Making Test A and Trail Making Test B. Patients had&#xD;
           cognitive dysfunction when two Z scores in individual tests or the combined Z score were&#xD;
           1.96 or more.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of postoperative cognitive dysfunction</measure>
    <time_frame>7 days after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of postoperative delirium</measure>
    <time_frame>3 days after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Postoperative Cognitive Dysfunction</condition>
  <condition>Postoperative Delirium</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine+routine PCIA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexmedetomidine 150ug is diluted to 150ml with 0.9% saline,continuous micro-pump infusion for 72 hours with 2ml/h speed.Routine patient controlled intravenous analgesia(PCIA) formula is sufentanyl(0.06ug.kg-1.h-1),diluted to 150ml with 0.9% saline,continuous micro-pump infusion for 72 hours with 2ml/h speed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Routine PCIA</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Routine patient controlled intravenous analgesia(PCIA) formula is sufentanyl(0.06ug.kg-1.h-1),diluted to 150ml with 0.9% saline,continuous micro-pump infusion for 72 hours with 2ml/h speed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine 150ug is diluted to 150ml with 0.9% saline,continuous micro-pump infusion for 72 hours with 2ml/h speed.</description>
    <arm_group_label>Dexmedetomidine+routine PCIA</arm_group_label>
    <other_name>Dexmedetomidine Hydrochloride Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sufentanyl</intervention_name>
    <description>Sufentanyl(0.06ug.kg-1.h-1) is diluted to 150ml with 0.9% saline,continuous micro-pump infusion for 72 hours with 2ml/h speed.</description>
    <arm_group_label>Dexmedetomidine+routine PCIA</arm_group_label>
    <arm_group_label>Routine PCIA</arm_group_label>
    <other_name>Sufentanil Citrate Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Saline is used to dilute other drugs</description>
    <arm_group_label>Dexmedetomidine+routine PCIA</arm_group_label>
    <arm_group_label>Routine PCIA</arm_group_label>
    <other_name>normal saline,physiological saline,NS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients' age ≥65 years&#xD;
&#xD;
          -  Underwent elective non-cardiac surgery under general anesthesia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with severe bradycardia (heart rate&lt;55bpm)&#xD;
&#xD;
          -  Severe arrhythmia or cardiac dysfunction (ejection fraction&lt;35%)&#xD;
&#xD;
          -  Mini-Mental Scale Test (MMSE) Exclusion criteria: illiteracy &lt;18, primary school &lt;21,&#xD;
             junior school and above &lt;25&#xD;
&#xD;
          -  Preoperative clear systems and spiritual history of neurological disease or long-term&#xD;
             use of sedatives or antidepressants&#xD;
&#xD;
          -  History of alcohol abuse or a history of drug dependence&#xD;
&#xD;
          -  Have brain surgery or trauma&#xD;
&#xD;
          -  Severe vision or hearing impairment&#xD;
&#xD;
          -  Cannot with the completion of tests of cognitive function&#xD;
&#xD;
          -  Refused to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kangjie Xie, MD</last_name>
    <phone>008613516721870</phone>
    <email>xkj1243@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>September 11, 2016</study_first_submitted>
  <study_first_submitted_qc>October 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2016</study_first_posted>
  <last_update_submitted>October 8, 2016</last_update_submitted>
  <last_update_submitted_qc>October 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
    <mesh_term>Postoperative Cognitive Complications</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sufentanil</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Dsuvia</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

